Novo Nordisk Diabetes Meds - Search News

FDA Declares Shortage of Novo Nordisk's Wegovy, Ozempic

The Associated Press on MSN · 1h

Yearslong shortage of popular weight-loss and diabetes drugs is resolved, FDA says

In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., also had been resolved. Zepbound is approved to treat obesity and Mounjaro is approved for diabetes. They use the same active ingredient, tirzepatide.

NBC New York · 9h

Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.

USA TODAY on MSN · 5h

Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.

5hon MSN

Novo’s Ozempic Shortage Is Declared Over, Hitting Copycats

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...

FiercePharma10h

Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Dozens of attorneys general urge FDA to crack down on counterfeit obesity drugs

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results